We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eagle Pharmaceuticals is objecting to the FDA’s decision to grant orphan drug Bendeka only three years of exclusivity instead of the full seven years and says it may take action. Read More
The UK’s National Institute for Health and Care Excellence has recommended against reimbursing Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi, saying benefits related to lung function were unlikely to be clinically significant. Read More